Introduction of NAFLD and NASH
       Nonalcoholic fatty liver disease (NAFLD) is defined as lipid-deposit accumulation in the hepatocytes, which is not due to excessive alcohol use. NAFLD encompasses a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which in its most severe form can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. The NAFLD disorder has a prevalence of 15–20% in the general population and 76–90% in the obese. It is estimated that more than 1/3 of the population worldwide will be a risk in NAFLD, which is significantly exceeding an incidence of Hepatitis B, Hepatitis C, and Alcoholic Liver Disease. NAFLD is now the most common disease of the Liver.

Innovative Candidate Compounds for NASH treatment
ABP-6016 is a novel drug candidate for NASH treatment with a remarkable potency and very well tolerance in mice. It shows excellent efficacy in various NASH animal models by significantly relieving fatty degeneration of the liver, reducing the inflammatory reaction, anti-oxidant effect and etc. Low toxicity and good tolerance are shown in the pre-clinical study. It is expected to be a new generation of innovative medicine for NASH treatment.